✦ LIBER ✦

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a

✍ Scribed by Hoffmann, R; Müller, I; Neuber, K; Lassmann, S; Buer, J; Probst, M; Oevermann, K; Franzke, A; Kirchner, H; Ganser, A

Book ID: 109838646
Publisher: Nature Publishing Group
Year: 1998
Tongue: English
Weight: 700 KB
Volume: 78
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1998.630

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chemoimmunotherapy with dacarbazine, cis

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group

✍ C.J.A. Punt; S. Suciu; M.A. Gore; J. Koller; W.H.J. Kruit; J. Thomas; P. Patel; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Induction of tyrosinase-reactive T cells

Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha ± interleukin-2 in patients with metastatic melanoma

✍ Alexander Schmittel; Ulrich Keilholz; Regina Max; Eckhard Thiel; Carmen Scheiben 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 92 KB 👁 2 views

We have shown the presence of tyrosinase-reactive T cells in the peripheral blood of melanoma patients, who had been in remission after treatment with IL-2-containing regimens. In this consecutive study, we analyzed the T-cell response to various peptides derived from tyrosinase in serial blood samp